IMUX Immunic Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMUX

Price (delayed)

$1.37

Market cap

$123.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.11

Enterprise value

$77.17M

Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's ...

Highlights
The EPS has increased by 44% YoY and by 35% from the previous quarter
The company's debt fell by 36% YoY and by 19% QoQ
The quick ratio has plunged by 79% YoY and by 44% from the previous quarter
IMUX's equity has dropped by 75% year-on-year and by 40% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.immunic-therapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IMUX
Market
Shares outstanding
89.93M
Market cap
$123.2M
Enterprise value
$77.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.14
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$93.61M
EBITDA
-$93.5M
Free cash flow
-$71.16M
Per share
EPS
-$2.11
Free cash flow per share
-$1.61
Book value per share
$0.64
Revenue per share
$0
TBVPS
$1.23
Balance sheet
Total assets
$54.3M
Total liabilities
$25.37M
Debt
$639,000
Equity
$28.93M
Working capital
$27.81M
Liquidity
Debt to equity
0.02
Current ratio
2.12
Quick ratio
1.89
Net debt/EBITDA
0.49
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-117.4%
Return on equity
-157.4%
Return on invested capital
N/A
Return on capital employed
-316.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMUX stock price

How has the Immunic stock price performed over time
Intraday
3.01%
1 week
12.3%
1 month
12.3%
1 year
-20.81%
YTD
-8.67%
QTD
3.79%

Financial performance

How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.22M
Net income
-$93.61M
Gross margin
N/A
Net margin
N/A
Immunic's net income has increased by 27% QoQ and by 22% YoY
IMUX's operating income is up by 25% since the previous quarter and by 17% year-on-year

Growth

What is Immunic's growth rate over time

Valuation

What is Immunic stock price valuation
P/E
N/A
P/B
2.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 44% YoY and by 35% from the previous quarter
IMUX's equity has dropped by 75% year-on-year and by 40% since the previous quarter
The price to book (P/B) is 43% higher than the 5-year quarterly average of 1.5 and 43% higher than the last 4 quarters average of 1.5

Efficiency

How efficient is Immunic business performance
The company's return on equity has shrunk by 60% YoY
The company's return on assets fell by 31% YoY but it rose by 10% QoQ

Dividends

What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMUX.

Financial health

How did Immunic financials performed over time
The total assets is 114% greater than the total liabilities
IMUX's total liabilities has surged by 80% year-on-year and by 37% since the previous quarter
The quick ratio has plunged by 79% YoY and by 44% from the previous quarter
The company's debt is 98% lower than its equity
The company's debt to equity has surged by 100% YoY
IMUX's equity has dropped by 75% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.